The amended Pharmaceutical Affairs Act embracing the Patent Linkage System, among others, devised to foster better development of the new biomedical industry in Taiwan through early resolution of patent disputes between brand drug companies and generic drug companies, was promulgated on December 29, 2017. It is expected that the Patent Linkage System will be implemented by early 2019 subsequent to the enactment of the amended Pharmaceutical Affair Act.
The patent linkage system is briefly introduced in a newsletter published on the website of our firm. Below is a flowchart, drawn in accordance with the draft of “the Enforcement Rules for Patent Linkage” completed by Taiwan’s FDA recently, which provides details of how to file an application for recording patent information relating to a patent to be listed in the linkage system so as to prevent Taiwan’s FDA from granting regulatory authorization to a generic medicine.
According to the draft, the onus is placed on the owner of a new drug approval, instead of the patentee, to file the application. The application must be filed within 45 days from the date the certificate of a new drug approval is received or 3 months from the implementation of the Patent Linkage System if the certificate of a new drug approval is issued before the patent linkage system is implemented.
Only invention patents for compounds, compositions or formulations, as well as medical uses are allowed to be listed:
i. Compound: the active ingredient(s) of a drug;
ii. Composition or formulation: the composition or formulation of the active ingredients of a drug; and
iii. Medical use: the medical use(s) corresponding to all or part of the indication(s) on the certificate of drug approval.
In general, the information regarding a patent to be listed that need be submitted for recordation in the registration system includes: the patent number and expiry date of the patent, as well as the name of the patent owner, exclusive licensee and patent attorney. For a patent relating to medical use, the number(s) of the Claim(s) corresponding to an indication(s) identified on the certificate of the new drug approval must be specified. Any changes, including an extension of the patent term, claim amendments, revocation of the patent, and ownership or patent attorney change, must be updated within 45 days from the date when such change occurs.
To prevent abuse of the right of the new drug owner, the patent information recorded in the registration system will be open to the public for inspection. If a third party finds out that any of the recorded information is questionable, such as the listed patent is not related to a compound, composition or formulation, or a medical use, or there is not an update of a listed patent, he may file a statement with Taiwan’s FDA in writing along with evidence. Taiwan’s FDA will serve a copy of the submitted statement with evidence on the owner of the new drug approval within 20 days from the date the statement and evidence is received. The owner of the new drug approval may file a counterstatement in writing, make a correction, or remove the listed patent within 45 days from the date he receives the statement and evidence from Taiwan's FDA.
It is against the Fair Trade Act and is criminally liable for the owner of a new drug approval to file an application for recording incorrect patent information regarding a listed patent by fraud or deception, with an attempt to prevent generic drugs from obtaining drug approval. Therefore, it is worth noting that all patent information to be recorded should be correct and up-to-date.
